Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: evidence from the RESTORE trial
P Mitchell, L Annemans, M Gallagher… - British journal of …, 2012 - bjo.bmj.com
Background/aims To evaluate the cost-effectiveness of ranibizumab as either monotherapy
or combined with laser therapy, compared with laser monotherapy, in the treatment of …
or combined with laser therapy, compared with laser monotherapy, in the treatment of …